Chargement en cours...
Contradictory KRAS mutation test results in a patient with metastatic colon cancer: A clinical dilemma in the era of personalized medicine
The KRAS oncogene is mutated in 40‒50% of colorectal cancers and confers resistance to EGFR-targeted therapy. In the clinic, agents such as cetuximab or panitumumab target the EGFR receptor for therapeutic benefit. Cetuximab was approved by the FDA in 2012 as first-line therapy for KRAS mutation-neg...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Landes Bioscience
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3841208/ https://ncbi.nlm.nih.gov/pubmed/23792572 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.25095 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|